144.46

2.77% 4.15

Palvella Therapeutics Inc (PVLA)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$140.31

Offen:

$141.49

24-Stunden-Volumen:

102.53K

Relative Volume:

0.39

Marktkapitalisierung:

$2.08B

Einnahmen:

$1.30M

Nettoeinkommen (Verlust:

$-49.30M

KGV:

-34.65

EPS:

-4.1688

Netto-Cashflow:

$-25.01M

1W Leistung:

-5.64%

1M Leistung:

+32.70%

6M Leistung:

+42.73%

1J Leistung:

+479.12%

1-Tages-Spanne:

$138.29

$147.96

1-Wochen-Bereich:

$135.00

$150.40

52-Wochen-Spanne:

$24.07

$161.38

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Firmenname

Palvella Therapeutics Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

(484) 253-1461

Adresse

353 W. LANCASTER AVENUE, WAYNE

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

PVLA's Discussions on Twitter

Compare PVLA vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PVLA Palvella Therapeutics Inc	144.72	2.01B	1.30M	-49.30M	-25.01M	-4.1688
VRTX Vertex Pharmaceuticals Inc	522.41	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.94	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	915.98	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.29	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.97	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-07	Eingeleitet	Mizuho	Outperform
2025-12-05	Eingeleitet	BTIG Research	Buy
2025-12-04	Eingeleitet	Craig Hallum	Buy
2025-11-19	Hochstufung	Raymond James	Outperform → Strong Buy
2025-09-09	Eingeleitet	Oppenheimer	Outperform
2025-08-06	Eingeleitet	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-04-09	Eingeleitet	Chardan Capital Markets	Buy
2025-03-26	Eingeleitet	Stifel	Buy
2025-03-07	Eingeleitet	Scotiabank	Sector Outperform
2025-02-20	Eingeleitet	Canaccord Genuity	Buy
2025-02-05	Eingeleitet	TD Cowen	Buy
2024-12-26	Eingeleitet	H.C. Wainwright	Buy
2024-12-18	Eingeleitet	Cantor Fitzgerald	Overweight
2020-03-13	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-07-30	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-05-14	Eingeleitet	Robert W. Baird	Outperform
2018-03-19	Eingeleitet	Evercore ISI	Outperform
2018-03-19	Eingeleitet	Jefferies	Buy
2018-01-16	Bestätigt	H.C. Wainwright	Buy
2017-05-30	Eingeleitet	Rodman & Renshaw	Buy
2016-08-05	Fortgesetzt	ROTH Capital	Buy
2015-08-12	Eingeleitet	JMP Securities	Mkt Outperform
2015-07-27	Eingeleitet	Oppenheimer	Outperform
2015-07-22	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten

Jul 04, 2026

PVLAPalvella Therapeutics Inc Volatility & Greeks - Finviz

Jul 04, 2026

Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView

Jul 04, 2026

Jul 01, 2026

Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo

Jul 01, 2026

Jun 30, 2026

Palvella Therapeutics Adds Rare Disease Executive Matt Pauls to Board of Directors - citybiz

Jun 30, 2026

Palvella Therapeutics, Inc. Files Form 8-K: Key Company Details, Stock Info, and Contact Information (June 2026) - Minichart

Jun 30, 2026

Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com - Investing.com South Africa

Jun 30, 2026

Palvella Therapeutics appoints Matt Pauls to board of directors - Investing.com

Jun 30, 2026

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail

Jun 30, 2026

Palvella Therapeutics Appoints Accomplished Rare Disease - GlobeNewswire

Jun 30, 2026

Jun 29, 2026

Palvella Therapeutics stock hits 52-week high at 151.36 USD - Investing.com

Jun 29, 2026

Palvella Therapeutics stock hits 52-week high at 151.36 USD By Investing.com - Investing.com Nigeria

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com

Jun 29, 2026

Palvella submits FDA NDA for QTORIN gel - grafa.com

Jun 29, 2026

Palvella submits first module of NDA for rare skin disease therapy - Investing.com

Jun 29, 2026

Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations - Quiver Quantitative

Jun 29, 2026

Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - Yahoo Finance

Jun 27, 2026

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - The Motley Fool

Jun 27, 2026

Jun 26, 2026

Price to earnings forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView

Jun 26, 2026

Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA) - TradingView

Jun 26, 2026